V. Study assessment table (SCIT)

		HBV testing[2]	Pregnancy test[3]	Concomittant Medication	ECOG / disease-related B-symptoms	Height / Weight / BSA	Physical examination	Radiological assessment[4]	ECG / LVEF	Complete blood count[5]	Serum chemistry[6]	Quality of life (QoL)[7]	FISH cytogenetics, TP53 and IGHV (central lab Ulm)	MRD from peripheral blood (central lab Kiel)	Accompanying scientific program	Bone marrow aspirate/biopsy[8]	MRD from bone marrow[8] (central lab Kiel)	Response assessment	New treatment and survival status	i.v. administration of Rituximab	i.v. administration of Bendamustin	i.v. administration of Fludarabine and Cyclophosphamid	(serious) adverse events[9]
Cycle 1-6	day 1[1]	(x)	(x)	CONTINUOUS REPORTING		X	O			X	X			X[10]	X[11, 12]					X	X	X	CONTINUOUS REPORTING
	days 2/(3)																				X	X	
	days 8/15/22									O	O												
Interim staging[13]					X		X	(x)	O	X	X	X	X[12]		X[12]			X	X				
Initial response assessment[14]					X		X	(x)	O	X	X	X	X[12]		X[12]			X	X				
Final restaging[15]		(x)	(x)		X		X	X	O	X	X		X[12]		X[12]	X	X	X	X				
MRD-Staging 1[16]									O			X	X[12]	X	X[12]			X	X				
MRD-Staging 2 [MO13][17]		(x)			X		X	(x)	O	X	X	X	X[12]	X	X[12]			X	X				
MRD-Staging 3 [MO15][18]		(x)			X		X	(x)	O	X	X	X	X[12]	X	X[12]			X	X				
Follow-up until PD[19]		(x)			X		X	(x)	O	X	O	X[20]	X[12]		X[12]			X	X				
Follow-up after PD[21]					X				O			X[20]						X	X				

10)C1D1 en C2D1; 11) C2D1; 12) bij progressie

X = assessment mandatory, (x) = assessment mandatory in certain patients/situations, O = assessment recommended, but not documented in the CRF.

For all tests in the study a time window of +/- 2 days is appropriate.